NUS Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa, ageLOC LumiSpa iO, and Nu Skin RenuSpa iO; ageLOC TruFace and ageLOC LumiSpa cleansers and devices; Prysm iO, a data-enabled wellness device; and Nutricentials beauty and Beauty Focus wellness brands. The company also provides wellness products, such as ageLOC TRME, LifePak, and Beauty Focus. In addition, it is the research and product development of skin care products, nutritional supplements, and devices. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center and independent marketers. It serves Mainland China; South Korea; Southeast Asia/Pacific, which includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Australia, New Zealand and other markets; Americas, comprising Canada, Latin America and the United States; Japan; Hong Kong/Taiwan, consists of Macau; and Europe & Africa, which includes markets in Europe as well as South Africa. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.…
Industry Peers
Household & Personal ProductsKey Statistics
About Nu Skin Enterprises (NYSE: NUS)
›
Nu Skin Enterprises (NYSE: NUS) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Household & Personal Products industry, part of the Consumer Defensive sector, and reports about 2,800 employees.
The shares were at 3.770 USD on 19 November 2026, down 60.3% over 52 weeks. Its 52-week range is 3.755 USD to 11.67 USD, and it trades at the bottom of that range.
Its market capitalisation is 183.52M USD. It pays a dividend yielding 6.20% (it pays out 22% of its earnings), against a median of 2.58% among the dividend payers in that peer group.
Nu Skin Enterprises reports return on equity of 19.9%, an operating margin of 4.1% and revenue down 14.6% year over year.
Its debt exceeds its cash by 110.68M USD, a debt-to-equity ratio of 0.38. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 12.48 USD is 231.0% above the current price. The next earnings report is expected on 11 February 2027.